Alpine Global Management’s Arbutus Biopharma ABUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-10,198
Closed -$24K 136
2022
Q4
$24K Buy
+10,198
New +$24.4K 0.01% 419
2021
Q1
Sell
-35,825
Closed -$127K 306
2020
Q4
$127K Buy
+35,825
New +$125K 0.03% 145
2016
Q2
Sell
-10,434
Closed -$43K 186
2016
Q1
$43K Buy
+10,434
New +$37.3K 0.01% 145

Other funds holding ABUS

Alpine Global Management's ABUS Position: Q1 2023 in Review

Alpine Global Management sold out of Arbutus Biopharma (ABUS) in Q1 2023, closing a stake of 10,198 shares — an estimated $24K sold.

Alpine Global Management first reported a position in ABUS in Q1 2016 and held it in 3 quarters. The position peaked at $127K in Q4 2020. 122 funds tracked by Wall St. Rank hold ABUS as of Q1 2023.

  • Alpine Global Management reported no remaining Arbutus Biopharma position as of Q1 2023 after selling out during the quarter.
  • Alpine Global Management sold 10,198 Arbutus Biopharma shares in Q1 2023, an estimated $24K.
  • Alpine Global Management first reported a position in Arbutus Biopharma in Q1 2016 and held it in 3 quarters.
  • Alpine Global Management's Arbutus Biopharma position peaked at $127K in Q4 2020.
  • 122 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2023.

Based on Alpine Global Management's 13F filing for Q1 2023, filed 15 May 2023.